24-hour inhibition of BTK was maintained at 100% in PBMCs and 94% to 100% in lymph nodes when taken at the recommended total daily dose of 320 mg. The clinical significance of 100% inhibition has not been established.1,2
BTK=Bruton’s tyrosine kinase; PBMCs=peripheral blood mononuclear cells. R/R=relapsed/refractory.
BRUKINSA® (zanubrutinib) is a kinase inhibitor indicated for the treatment of adult patients with:
- • Waldenström’s macroglobulinemia (WM).
- • Mantle cell lymphoma (MCL) who have received at least one prior therapy.
- • Relapsed or refractory marginal zone lymphoma (MZL) who have received at least one anti-CD20-based regimen.
IMPORTANT SAFETY INFORMATION
WARNINGS AND PRECAUTIONS
Fatal and serious hemorrhagic events have occurred in patients with hematological malignancies treated with BRUKINSA monotherapy. Grade 3 or higher hemorrhage events including intracranial and gastrointestinal hemorrhage, hematuria and hemothorax have been reported in 3.4% of patients treated with BRUKINSA monotherapy. Hemorrhage events of any grade occurred in 35% of patients treated with BRUKINSA monotherapy.
Bleeding events have occurred in patients with and without concomitant antiplatelet or anticoagulation therapy. Co-administration of BRUKINSA with antiplatelet or anticoagulant medications may further increase the risk of hemorrhage.
Monitor for signs and symptoms of bleeding. Discontinue BRUKINSA if intracranial hemorrhage of any grade occurs. Consider the benefit-risk of withholding BRUKINSA for 3-7 days pre- and post-surgery depending upon the type of surgery and the risk of bleeding.
DEMONSTRATED TO PROVIDE